Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06302621 · ClinicalTrials.gov registry record · Phase 1

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 1
Development phase
70
Enrollment target
1
Study location

NCT06302621 is a Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 70 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06302621, a Phase 1 study of Advanced Solid Tumor and Cholangiocarcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.

Conditions Studied

Advanced Solid Tumor Cholangiocarcinoma Metastatic Solid Tumor Unresectable Solid Tumor

Interventions

  • DRUG Afatinib
  • DRUG Pemigatinib

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-04-17
Est. Completion 2027-12-01
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06302621

The ClinicalTrials.gov registry entry for NCT06302621 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Afatinib is the first listed.

NCT06302621 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06302621 about?

NCT06302621 is a clinical study titled "Pemigatinib + Afatinib in Advanced Refractory Solid Tumors". This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable si...

What is the current status of trial NCT06302621?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-04-17. Estimated completion is 2027-12-01.

What conditions does trial NCT06302621 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Cholangiocarcinoma, Metastatic Solid Tumor, Unresectable Solid Tumor.

What interventions are being tested in trial NCT06302621?

The interventions under investigation include: Afatinib (DRUG), Pemigatinib (DRUG).

Who is sponsoring clinical trial NCT06302621?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06302621 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Cholangiocarcinoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.